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ABSTRACT
The number of the elderly individuals is steeply increasing, and their absolute cardiovascular 
risk is higher than that of younger age groups. However, very few statin trials have included 
elderly patients alone. Recently, we published the SCOPE-75 study, which analyzed the 
effect of statins for primary prevention in elderly Koreans (>75 years). In this study, statin 
users showed significantly fewer cardiovascular events and a lower all-cause mortality rate, 
supporting more active use of statins in this population. In the current review, we further 
compare and discuss similar studies reported in the past decades and in recent years.
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INTRODUCTION
The prevalence of atherosclerotic cardiovascular disease (ASCVD) increases progressively 
with age.1 Individuals more than 75 years of age are more than 3 times as susceptible to 
cardiovascular mortality than younger age groups. Thus, primary prevention in this group 
is critical.2,3 However, most randomized trials have excluded older patients, resulting in 
insufficient clinical evidence for primary cardiovascular prevention in this population.4,5
We recently analyzed the effect of statins on clinical outcomes for primary prevention 
in patients aged >75 years. Here, we present the major results of that study and review 
other recent studies on the same topic, with a focus on the effects of statins for primary 
prevention in the elderly.
CURRENT STATIN GUIDELINES AND KNOWLEDGE GAPS 
REGARDING THE ELDERLY POPULATION
The 2018 American College of Cardiology/American Heart Association (ACC/AHA) and the 
2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines 
were recently released.6,7 In Korea, the latest guideline for the management of dyslipidemia 
was released in 2019.8 However, these guidelines contain gaps regarding statin use in the 
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elderly population; these gaps derive from concerns regarding frailty, multimorbidity, 
polypharmacy, and functional limitations in the elderly.9 Furthermore, each of these 
guidelines uses a different age threshold (Table 1). The recently published ESC/EAS guideline 
extended the age of the risk assessment system from 65 to 70, and recommended statin 
use for primary prevention according to individuals' level of risk until age 75.7 With this in 
mind, we have defined “elderly” as referring to individuals aged over 75 herein. We reviewed 
previous randomized controlled trials (RCTs), meta-analyses, and studies on statin therapy 
for primary statin prevention published since 2018.
STATINS AND CLINICAL OUTCOMES OF PRIMARY 
PREVENTION IN INDIVIDUALS AGED >75 YEARS: THE 
SCOPE-75 STUDY
We recently conducted the SCOPE-75 study, which included patients aged >75 years who had 
at least 1 cardiovascular risk factor.10 In this retrospective, propensity score-matched study, 
we analyzed 639 statin users and 639 statin non-users. At a median follow-up of 5.2 years, 
statin users showed lower rates of major adverse cardiovascular and cerebrovascular events 
(1.25 vs 2.15 events/100 person-years; hazard ratio [HR], 0.59; 95% confidence interval 
[CI], 0.40–0.85; p=0.005) and all-cause mortality (0.65 vs. 1.19 events/100 person-years; 
HR, 0.56; 95% CI, 0.34–0.93; p=0.02). The HRs were the same for each outcome variable in 
Kaplan-Meier curves (Fig. 1). In this study, statin use was associated with a minimal increase 
of new-onset diabetes, but showed no association with new-onset cancers. This study 
shed light on the controversial issue of statin use for primary prevention in the elderly by 
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Table 1. Comments on elderly patients in the latest guidelines
Guideline ESC/EAS 20197 ACC/AHA 20186 Korea 20188
Age (yr) 40–75 40–75 30–65
Risk assessment SCORE (40 to 70 yr) Pooled cohort equation (≤79 yr) No. of risk factors
Risk threshold 
for therapy
• High risk: 5% to 10%
• Very high risk: ≥10%
• High risk: ≥20%
• Intermediate risk: 7.5% to 20%
•  Very high risk: coronary artery disease, 
atherosclerotic ischemic stroke and transient 
ischemic attack, peripheral artery disease
•  High risk: carotid artery disease, abdominal 
aneurysm, diabetes
• Intermediate: ≥2 RFs




• Very high: 70 mg/dL
• High: 100 mg/dL
• ≥190 mg/dL
• Adults with diabetes
• Very high: ≥70 mg/dL
• High: ≥100 mg/dL
• Intermediate: ≥130 mg/dL
• Low: ≥160 mg/dL
Target • Very high: <55 mg/dL
• High: <70 mg/dL
• Intermediate or low: <115 mg/dL
• High: 50% or more decrease
• Intermediate: 30% decrease
• Very high: <70 mg/dL
• High: <100 mg/dL
• Intermediate: <130 mg/dL
• Low: <160 mg/dL
Comment for 
elderly
• 65 to <75 yr: according to level of risk
•  >75 yr: at high risk or above, initiation of 
statin prevention
 •  Statin therapy should be started at a low 
dose if there is significant renal impairment 
and/or the potential for drug interactions, 
and then titrated upwards to achieve LDL-C 
treatment goals
• Not strong evidence for patients aged >75 yr
•  Moderate-intensity statin use for patients 
aged >75 yr with 70 to 189 mg/dL may be 
reasonable
•  The primary preventive effects of statins on 
older adults aged ≥70 yr have been proven
• ≥80 yr: evidence is lacking
•  Statins should be used while carefully 
monitoring their interactions with other 
drugs and adverse reactions
ACC/AHA, American College of Cardiology/American Heart Association; ESC/EAS, European Society of Cardiology/European Atherosclerosis Society; LDL-C, low-
density lipoprotein cholesterol; RF, risk factor.
providing evidence of an association between statin use and cardiovascular risk reduction in 
people aged >75 years.
PRIOR STUDIES PERFORMED IN MIXED POPULATIONS
Several clinical trials have provided evidence that statin use is beneficial for primary 
prevention in patients aged >75 years11 Patients in this age range were included in trials such 
as Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese 
(MEGA)12 and Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating 
Rosuvastatin (JUPITER) (Table 2).13,14 The Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial-Lipid Lowering Trial (ALLHAT-LLT)15,16 and PROspective Study of 
Pravastatin in the Elderly at Risk (PROSPER)17 trials enrolled patients aged 65–82. However, 
these studies contained mixed populations for primary and secondary prevention. These RCTs 
showed significant cardiovascular risk reduction in statin users, and the results were consistent 
in patients aged 66–75 years. Furthermore, 2 meta-analyses by Savarese et al.18 and Ridker et 
al.19 showed benefits of statin use for primary prevention in patients aged >65 years. Savarese 
et al.18 analyzed patients aged ≥65 years in 8 clinical trials and showed a relative risk reduction 
of 39.4% for myocardial infarction and 23.8% for stroke. Although the risk of all-cause and 
cardiovascular death was also reduced, that reduction was not statistically significant. The study 
by Ridker et al. 19 included the JUPITER and Heart Outcomes Prevention Evaluation-3 (HOPE-3) 
trials and analyzed 3 age groups: <65 years, 65 to <70 years, and ≥70 years. In all groups, statin 
therapy reduced cardiovascular risk (Table 2). A meta-analysis by the Cholesterol Treatment 
Trialists' Collaboration20 analyzed 186,864 patients from 28 clinical trials, of whom 14,483 
(8%) were older than 75 years. In that study, statin therapy reduced major vascular events by 
21% per 1.0 mmol/L decrease in low-density lipoprotein cholesterol. In the subgroup of elderly 
individuals (>75 years of age), statins were also associated with fewer vascular events (relative 
ratio [RR], 0.79; 95% CI, 0.77–0.81). However, for primary prevention in patients aged >75 
years, the risk reduction was not significant (RR, 0.92; 95% CI, 0.73–1.16).20
3https://doi.org/10.12997/jla.2020.9.1.1
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Fig. 1. Incidence of MACCE and all-cause mortality in the SCOPE-75 study (from Kim et al.10 with permission). 
MACCE, major adverse cardiac and cerebrovascular events; HR, hazard ratio.
STUDIES IN 2018 AND 2019 FOCUSING ONLY ON THE 
ELDERLY
Four retrospective studies—including ours—that analyzed the effects of statins for 
primary prevention in the elderly were published in 2018 and 2019 (Table 3).21 Ramos et 
al.22 analyzed 46,864 patients older than 74 with or without diabetes. In their study, statin 
users with diabetes showed significantly reduced risks of ASCVD (HR, 0.76; 95% CI, 
0.65–0.89) and all-cause death (HR, 0.84; 95% CI, 0.75–0.94). However, statin treatment 
was not associated with a reduced risk of ASCVD (HR, 0.94; 95% CI, 0.86–1.04) or all-
cause mortality (HR, 0.98; 95% CI, 0.91–1.05) in participants without diabetes. Their study 
also included 8,307 patients aged >85 years, but statins did not show a significant benefit 
in this subgroup. Bezin et al.23 reported that cumulative statin use for primary prevention 
was associated with a lower risk of acute coronary syndrome (adjusted HR, 0.93; 95% CI, 
0.89–0.96) in patients aged 75 years or older who had modifiable risk factors. However, the 
benefits of statins were diminished in patients without risk factors (adjusted HR, 1.01; 95% 
CI, 0.86–1.18). Jun et al.24 conducted a nested case-control study using a Korean nationwide 
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Table 2. Prior studies on statin use for primary prevention that included mixed populations
Study Study design No. of patients Mean age  
(or range) (yr)
Outcome variables Findings (95% CI)
RCTs
ALLHAT-LLT15 •  Secondary analysis of RCT; usual 
care vs. pravastatin (40 mg)
• 10,355 • 66 
(>65: 55%)
• All-cause mortality
•  CHD events
• Death: RR, 0.99 (0.89–1.11)
• CHD: RR, 0.91 (0.79–1.04)
• Primary and secondary prevention
PROSPER17 •  RCT; placebo vs. pravastatin (40 mg) • 5,804 • 75  
(range 70–82)
•  Composite (CHD death, 
nonfatal MI, fatal or 
nonfatal stroke)
• 16.2% vs. 14.1%
• Primary and secondary prevention •  3,239 (primary 
prevention)
• HR, 0.85 (0.74–0.97)
• Primary prevention: no interaction
MEGA12 • RCT; diet vs. pravastatin (10–20 mg) • 3,966 • 58  
(>65: 23%)
•  CHD • 5.0% vs. 3.3%
• Primary prevention • HR, 0.67 (0.49–0.91)
• ≥60 yr: HR, 0.59 (0.40–0.88)
JUPITER13 •  RCT; placebo vs. rosuvastatin (20 mg) • 17,802 • 66  
(>65: 58%,  
≥70: 32%)*
•  Composite (MI, stroke, 
arterial revascularization, 
hospitalization for unstable 
angina, or CV death)
• 1.36%/yr vs. 0.77%/yr
• Primary prevention • 5,695 (>70 yr) • HR, 0.56 (0.46–0.69)
• >65 yr: no interaction
• ≥70 yr: HR, 0.61 (0.46–0.82)†
Meta-analyses
Savarese et al.18 • Meta-analysis of 8 trials; •  24,674 (only age 
≥65 yr)
• 73 •  MI, stroke, all-cause 
death, and CV death
• MI: RR, 0.606 (0.434–0.847)
- Lovastatin • Stroke: RR, 0.762 (0.626–0.926)
- Pravastatin • Death: RR, 0.941 (0.856–1.035)
- Atorvastatin • CV death: RR, 0.907 (0.66–1.199)
- Fluvastatin
- Rosuvastatin vs. placebo
• Primary prevention
Ridker et al.19 • Meta-analysis of 2 trials • 8,208 (65 to 70 yr) •  Composite (CV death, 
nonfatal MI, or nonfatal 
stroke)
• 65 to 70 yr: HR, 0.51 (0.38–0.69)
- JUPITER, HOPE-3 • 8,781 (≥70 yr) • ≥70 yr: HR, 0.74 (0.61–0.91)
- Placebo vs. rosuvastatin (10–20 mg)
CTT20 •  Meta-analysis of 28 RCTs; controls 
vs. statin
•  Primary and secondary prevention
• 186,854
• 14,483 (>75 yr)
• 78.8  
(>75 yr)




•  3.7% vs. 3.0%: RR, 0.79 (0.77–0.81) 
- >75 yr: RR, 0.87 (0.77–0.99)
•  Secondary: RR, 0.80 (0.77–0.82) 
 - >75 yr: RR, 0.85 (0.73–0.98)
•  Primary: RR, 0.92 (0.71–0.80) 
- >75 yr: RR, 0.92 (0.73–1.16) 
- Per 1 mmol/L reduction in LDL-C
CHD, coronary heart disease; CI, confidence interval; CTT, Cholesterol Treatment Trialists' Collaboration; CV, cardiovascular; HR, hazard ratio; LDL-C, low-density 
lipoprotein cholesterol; MI, myocardial infarction; RCT, randomized controlled trial; RR, relative ratio; JUPITER, Justification for the Use of Statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin; MEGA, Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; PROSPER, PROspective 
Study of Pravastatin in the Elderly at Risk; ALLHAT-LLT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid Lowering Trial.
*Reported by Ridker et al.19; †From secondary analysis reported by Glynn et al.14
cohort, focusing on the elderly aged ≥75 years. That study showed that concurrent statin 
treatment reduced cardiovascular composite outcomes (adjusted odds ratio, 0.77; 95% 
CI, 0.71–0.84). However, former use of statins had no effect on cardiovascular outcomes 
or all-cause death. Their study also showed that a longer duration of statin exposure was 
associated with fewer cardiovascular events.24 As mentioned above, the SCOPE-75 study by 
us showed significantly lower cardiovascular risk and all-cause mortality in statin users.10 
Collectively, these studies provide stronger evidence than was available before for the effects 
of statins on clinical outcomes. However, the lack of RCTs poses some limitations. The 
STAtins for Reducing Events in the Elderly (STAREE) trial, which is in progress, aims to 
determine the efficacy and safety of statins in elderly people aged ≥70 years.25 If properly 
finished, this trial might be able to provide more comprehensive information regarding the 
benefits and risks of statin use in the elderly population.
STATIN USE IN PATIENTS AGED OVER 85 YEARS
To date, data on statin use in patients aged over 85 years remain extremely limited. No risk 
scoring systems in current guidelines include this population. In the ESC/EAS and ACC/AHA 
guidelines, statin use for primary prevention in patients aged ≥85 is recommended, but at a 
weaker level.9,10 The National Institute for Health and Care Excellence (NICE)-UK guideline 
suggests that atorvastatin (20 mg) might be beneficial in this age group.26 Only the study by 
Ramos et al.25 separately analyzed individuals 85 years of age or older separately, and statins 
showed no benefits in this subgroup.
CONCLUSIONS
Studies performed in the past decade regarding the effects of statin use for primary 
prevention in individuals aged >75 years have shown possible clinical benefits. The SCOPE-75 
study by us and other very recent studies similarly revealed favorable clinical outcomes of 
statin use in this population. However, a further net-benefit analysis or a study of prospective 
data would strengthen the evidence base regarding this issue.
5https://doi.org/10.12997/jla.2020.9.1.1





Table 3. Studies published in 2018–2019 analyzing the effects of statin use for primary prevention in the elderly
Study Study design No. of 
patients
Mean age  
(or range) (yr)
Outcome variables Findings (95% CI)
Ramos et al.22 •  Retrospective cohort study; 





• Only ≥75  
(>85: 18%)
• ASCVD • ASCVD (non-diabetes, 75–84 years): RR, 1.00 (0.80–1.24)
• ASCVD (diabetes, 75–84 years): RR, 0.76 (0.65–0.89)
• ≥85 yr: non-significant
Bezin et al.23 •  Retrospective cohort study; 
statin non-users vs. statin users
• 7,284  
(≥75 yr)
• 80  
(77–84)
•  Composite (acute 
coronary syndrome, 
all-cause death)
• Secondary: adjusted HR, 0.75 (0.63–0.90)
•  Primary with modifiable risk factor: adjusted HR, 0.93 
(0.89–0.96)
•  Primary without modifiable risk factor: adjusted HR, 1.01 
(0.86–1.18)
•  Primary and secondary 
prevention
Jun et al.24 •  Retrospective case-control 
study; case vs. control subjects
• 66,102  
(≥75 yr)
• 84 •  Composite (MI, 
stroke, all-cause 
death)
• Adjusted OR, 0.77 (0.71–0.84)
•  Primary prevention
Kim et al.10 •  Retrospective cohort study; 
statin non-users vs. statin 
users
• 1,278  
(≥75 yr)
• 78  
(≥80: 30%)
•  Composite (CV 
death, MI, coronary 
revascularization, 
stroke)
• 2.15%/yr vs. 1.25%/yr
• HR, 0.59 (0.41–0.85)
ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; HR, hazard ratio; RR, relative ratio; OR, odds ratio; MI, myocardial infarction.
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